You are here: Industry Insights > Premas Biotech

News List

Akers Biosciences, Premas Biotech Announce SARS CoV-2 Positive Proof of Concept Results americanpharmaceuticalreview
August 28, 2020
Akers Biosciences announced with its partner, Premas Biotech, positive proof of concept results from Animal Studies conducted during a 4 week test of its SARS-CoV-2 vaccine candidate in mice.
Premas Biotech’s COVID-19 vaccine candidate sees neutralising immune response in animal studies expresspharma
August 28, 2020
The company announced that it is in talks with regulatory authorities for human trials of its triple antigen vaccine.
Premas Biotech initiates triple antigen VLP COVID-19 vaccine candidate for animal trials expresspharma
July 09, 2020
At the moment, it is the only one from India to adopt a triple-antigen approach that is designed to produce an enhanced immune response.
Akers, Premas Biotech Announce Successful Completion of Vaccine Prototype americanpharmaceuticalreview
May 20, 2020
Akers Biosciences announced Premas Biotech, its partner in the development of a vaccine candidate that is seeking to address the COVID-19 pandemic, has successfully completed its vaccine prototype.
Premas Biotech announces completion of vaccine prototype of triple-antigen candidate against COVID-1 expresspharma
May 20, 2020
Reportedly, the vaccine prototype is among the first in the world for VLP of SARS CoV-2 virus.
Premas Biotech announces development of vaccine against COVID-19 expresspharma
May 05, 2020
The triple antigen vaccine being developed by Premas Biotech is being designed to try to overcome presently known and possible future mutations of novel coronavirus.
Akers Biosciences, Premas Biotech Announce Progress in its Vaccine Development for COVID-19 americanpharmaceuticalreview
April 10, 2020
Akers Biosciences announced its collaboration with Premas Biotech has successfully completed the milestone of obtaining clones of all three coronavirus antigens, Spike (S) ...
Akers, Premas Progress Covid-19 Vax Development contractpharma
April 07, 2020
Akers Biosciences collaboration with Premas Biotech has successfully completed the milestone of obtaining clones of all three coronavirus antigens, Spike (S), Envelope (E), and Membrane (M) that they have selected for their vaccine candidate.
Akers Biosciences Licenses Premas Coronavirus Vax Candidate contractpharma
March 26, 2020
Aims to accelerate development timeline leveraging the D-Crypt platform.